All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
HONG KONG – Biotech companies that have not yet generated any revenue can seek listing on the Main Board of the Hong Kong Stock Exchange (HKEX). The exchange proposed the new policy Friday as part of the effort to lure more firms to go public, bolstering Hong Kong's biotech development.